Exela Pharma Sciences Llc (United States) is linked to 1 FDA-registered manufacturing site. 27 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Exela Pharma Sciences Llc: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/exela-pharma-sciences-llc

Overview

Exela Pharma Sciences Llc is a pharmaceutical company headquartered in Lenoir, United States.

Registered manufacturing sites (1)

Physical sites registered with the US FDA and resolved to Exela Pharma Sciences Llc, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

27 FDA enforcement records linked to this company.

  • recall — Class II2025-09-17

    Failed Impurities/Degradation Specifications: out of specification results for arsenic in the impurities tested.

  • warning_letter2025-07-02

    FDA Warning Letter (drug product)

  • recall — Class II2025-04-02

    Lack of Assurance of Sterility

  • recall — Class I2023-11-29

    Presence of Particulate Matter: Silicone

  • recall — Class I2023-11-29

    Presence of Particulate Matter: Silicone

  • recall — Class I2023-11-29

    Presence of Particulate Matter: Silicone

  • recall — Class I2022-12-21

    Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration.

  • recall — Class I2022-12-21

    Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration.

  • recall — Class I2022-11-02

    Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration

  • recall — Class I2022-11-02

    Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration

  • recall — Class II2022-01-19

    Lack of Assurance of Sterility

  • warning_letter2021-04-09

    FDA Warning Letter (drug product)

  • recall — Class III2020-09-23

    Short Fill

  • 4832019-07-18

    Containers & Closures Clean, Sterilized, Pyrogen-free

  • 4832019-07-18

    Cleaning / Sanitizing / Maintenance

  • 4832019-07-18

    Procedures for sterile drug products

  • 4832019-07-18

    Environmental Monitoring System

  • 4832019-07-18

    Investigations of discrepancies, failures

  • 4832019-07-18

    Validation lacking for sterile drug products

  • 4832019-07-18

    Prepared for each batch, include complete information

  • recall — Class II2018-05-30

    Labeling: Label Mix-Up: bottle labeled as Diclofenac Sodium and Misoprostol 75 mg/0.2 mg contained Diclofenac Sodium and Misoprostol 50 mg/0.2 mg tablets.

  • 4832017-09-28

    Environmental Monitoring System

  • 4832017-09-28

    Strict control not exercised over labeling issued

  • 4832017-09-28

    Examinations documented

  • 4832017-09-28

    Calibration/Inspection/Checking not done

  • 4832017-09-28

    Handling and Storage to Prevent Contamination

  • 4832017-09-28

    Drug product label, outsourcer facility

For suppliers

Is this Exela Pharma Sciences Llc?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.